Annual Financial Report

ABZENA PLC

("Abzena", the "Company" or the "Group")

Annual Report and Accounts for Year Ended 31 March 2015

15 June 2015

Cambridge, UK - Abzena plc (AIM: ABZA), a life sciences company providing services and technologies that enable the development of better biopharmaceutical products, announces that copies of its Annual Report and Accounts for the year ended 31 March 2015 are now available on the "Investors" section of the Group's website at http://www.abzena.com/results-and-presentations.

Printed copies of the Annual Report and Accounts are available from the Company Secretary, Abzena plc, Babraham Research Campus, Babraham, Cambridge CB22 3AT, UK (Tel: +44 1223 903498).

Details of the Group's Annual General Meeting and relevant documentation will be distributed to shareholders in due course.

About Abzena

Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups.

Abzena is quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.

www.abzena.com

For more information, please contact:

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 1223 903498

Email: [email protected] or [email protected]

Christopher Golden and Ivonne Cantu

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 20 7397 8900

Mark Swallow, Chris Gardner or Pip Batty

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 20 7638 9571

Email: [email protected]